Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Differential expression of the MYC-Notch axis drives divergent responses to the front-line therapy in central and peripheral extensive-stage small-cell lung cancer.

MedComm·2025

Same author

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer.

Cancer immunology, immunotherapy : CII·2025

Same author

Lipid Metabolism Related Gene ACSL3 as a Biomarker for Predicting Immunotherapy Outcomes in Lung Adenocarcinoma.

Cancer research and treatment·2025

Same author

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study.

Journal of hematology & oncology·2024

Same author

AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2024

Same author

Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial.

Signal transduction and targeted therapy·2024

Search research articles

Related Experiment Video

Updated: Jul 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition).

Linlin Wang¹, Ying Liu², Wei Zhao³

¹Department of Radiation Oncology, Shandong First Medical University Affiliated Cancer Hospital, Jinan, China.

|July 7, 2026

Summary

Radiotherapy combined with immunotherapy shows promise for unresectable lung cancer. This updated consensus provides evidence-based recommendations for non-small cell lung cancer and small cell lung cancer treatment.

Keywords:

Expert consensus Immune checkpoint inhibitors Radiotherapy Radiotherapy combined with immunotherapy Unresectable lung cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Related Experiment Videos

Last Updated: Jul 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Radiation Oncology
Immunotherapy

Background:

The combination of radiotherapy and immunotherapy is a significant research area for unresectable lung cancer.
Synergistic mechanisms and clinical evidence highlight the therapeutic potential of this combined approach.

Purpose of the Study:

To systematically review high-quality evidence on radiotherapy combined with immunotherapy for unresectable lung cancer.
To update the 2024 consensus with the latest evidence-based recommendations and clinical guidance.

Main Methods:

Systematic review of recent high-quality evidence.
Expert consensus development through extensive discussion and revision.

Main Results:

The combined approach demonstrates promising therapeutic potential in unresectable lung cancer.
Updated recommendations provide practical guidance for clinical decision-making.

Conclusions:

Radiotherapy and immunotherapy combination is a key strategy for unresectable lung cancer.
The updated consensus reflects the latest advancements and clinical evidence in the field.